2003
Clopidogrel for Coronary Stenting
Gurbel P, Bliden K, Hiatt B, O’Connor C. Clopidogrel for Coronary Stenting. Circulation 2003, 107: 2908-2913. PMID: 12796140, DOI: 10.1161/01.cir.0000072771.11429.83.Peer-Reviewed Original ResearchMeSH KeywordsAdenosine DiphosphateAgedAspirinBiomarkersClopidogrelCoronary Artery DiseaseDose-Response Relationship, DrugDrug ResistanceFemaleFlow CytometryGenetic VariationHumansMalePlatelet AggregationPlatelet Aggregation InhibitorsPlatelet Glycoprotein GPIIb-IIIa ComplexP-SelectinStentsTiclopidineConceptsElective coronary stentingCoronary stentingPretreatment reactivityInterindividual variabilityAdverse ischemic eventsAlternative pharmacological strategiesPlatelet inhibitory responseDrug responseGlycoprotein IIb/IIIaIIb/IIIaIschemic eventsPlatelet inhibitionPlatelet reactivityStent thrombosisPharmacological strategiesBaseline aggregationCatheterization laboratoryInhibitory responsesClopidogrelL ADPPatientsP-selectinPlatelet aggregationStentingDaysThe early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition
Gurbel P, Bliden K, Hiatt B. The early antiplatelet effects of clopidogrel loading for coronary stenting and the long-term stability of inhibition. Journal Of Thrombosis And Haemostasis 2003, 1: 1319-1321. PMID: 12871340, DOI: 10.1046/j.1538-7836.2003.00184.x.Peer-Reviewed Original Research
2001
The drug-eluting stent: is it the Holy Grail?
Hiatt B, Carter A, Yeung A. The drug-eluting stent: is it the Holy Grail? Reviews In Cardiovascular Medicine 2001, 2: 190-6. PMID: 12439368.Peer-Reviewed Original ResearchConceptsDrug-eluting stentsIntimal hyperplasiaAdverse clinical eventsOnly effective treatmentMulticenter clinical trialSirolimus-coated stentsDrug-coated stentsBare metal stentsMinimal intimal hyperplasiaCoronary stentingRestenosis rateClinical eventsNegative remodelingClinical trialsComplex lesionsEffective treatmentStentsHyperplasiaRestenosisCardiologists